Form 8-K - Current report:
SEC Accession No. 0001599298-23-000050
Filing Date
2023-05-09
Accepted
2023-05-09 16:06:19
Documents
18
Period of Report
2023-05-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20230509.htm   iXBRL 8-K 37392
2 EX-99.1 a2023_prx0509xfirst-pati.htm EX-99.1 15061
7 a2023_prx0509xfirst-pati001.jpg GRAPHIC 259543
8 a2023_prx0509xfirst-pati002.jpg GRAPHIC 252843
9 a2023_prx0509xfirst-pati003.jpg GRAPHIC 267855
10 a2023_prx0509xfirst-pati004.jpg GRAPHIC 109593
  Complete submission text file 0001599298-23-000050.txt   1454284

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20230509.xsd EX-101.SCH 2159
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20230509_def.xml EX-101.DEF 15283
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20230509_lab.xml EX-101.LAB 29621
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20230509_pre.xml EX-101.PRE 15940
12 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20230509_htm.xml XML 11117
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 23901930
SIC: 2834 Pharmaceutical Preparations